Copyright
©The Author(s) 2024.
World J Diabetes. Mar 15, 2024; 15(3): 361-377
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.361
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.361
Table 6 Types of Sodium–glucose cotransporter 2 inhibitors and their recommended clinical dosage
| Name | Molecular formula | Recommended initial dosage | In China, Listed or not | Recommended dosage for prediabetes | Ref. |
| Canagliflozin | C24H25FO5S | 100 mg/day | No | – | – |
| Dapagliflozin | C21H25CIO6•C3H8O2 | 5 mg/day | Listed | 10 mg/day | Lundkvist et al[63] |
| Empagliflozin | C23H27CIO7 | 10 mg/day | No | 10 mg/day | Lee et al[64] |
| Ipragliflozin | C21H21FO5S | 50 mg/day | No | – | – |
| Luseogliflozin | C23H30O6S | 2.5 mg/day | No | – | – |
| Tofogliflozin | C22H26O6 | 5 mg/day | No | 40 mg/day | Pafili et al[65] |
- Citation: Ping WX, Hu S, Su JQ, Ouyang SY. Metabolic disorders in prediabetes: From mechanisms to therapeutic management. World J Diabetes 2024; 15(3): 361-377
- URL: https://www.wjgnet.com/1948-9358/full/v15/i3/361.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i3.361